Cargando…

OR25-02 Hunting The Magic Bullet In Treating Male Secondary Hypogonadism Associated With Metabolic Syndrome: Results Of a Prospective Study Comparing Liraglutide Vs. Gonadotropins

Disclosure: S. La Vignera: None. R.A. Condorelli: None. A.E. Calogero: None. R. Cannarella: None. E. Greco: None. A. Aversa: None. Background: Previously, we hypothesized a role for glucagon-like peptide-1 (GLP1) analogs in the treatment of male infertility (DOI: 10.1111/andr.13015), although no stu...

Descripción completa

Detalles Bibliográficos
Autores principales: La Vignera, Sandro, Condorelli, Rosita A, Calogero, Aldo E, Cannarella, Rossella, Greco, Emanuela, Aversa, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554582/
http://dx.doi.org/10.1210/jendso/bvad114.1701
_version_ 1785116446420893696
author La Vignera, Sandro
Condorelli, Rosita A
Calogero, Aldo E
Cannarella, Rossella
Greco, Emanuela
Aversa, Antonio
author_facet La Vignera, Sandro
Condorelli, Rosita A
Calogero, Aldo E
Cannarella, Rossella
Greco, Emanuela
Aversa, Antonio
author_sort La Vignera, Sandro
collection PubMed
description Disclosure: S. La Vignera: None. R.A. Condorelli: None. A.E. Calogero: None. R. Cannarella: None. E. Greco: None. A. Aversa: None. Background: Previously, we hypothesized a role for glucagon-like peptide-1 (GLP1) analogs in the treatment of male infertility (DOI: 10.1111/andr.13015), although no studies have so far investigated this issue. Purpose: To prospectively investigate the effects of treatment with liraglutide, a GLP1 analog, on reproductive and sexual function in men with functional hypogonadism of childbearing age. Patients and Methods: 110 obese men of childbearing age (18-35 years) with functional hypogonadism were enrolled and divided into three groups based on their desire to have children. Group A consisted of men actively seeking paternity, Group B of men who did not seek paternity, and Group C of men who had already fathered a child. Group A was treated with gonadotropins [urofollitropin 150 IU three times a week and human chorionic gonadotropin (hCG) 2000 IU twice a week], Group B with liraglutide (3 mg daily), and Group C with transdermal testosterone (60 mg daily). The following endpoints were measured at enrolment and after 4 months: anthropometric and metabolic parameters, gonadotropins, total testosterone, conventional sperm parameters (Group A and B only), the score of the International Index of Erectile Function 5 Items (IIEF5), and frequency of phosphodiesterase type 5 inhibitors (PDE5i) use. Results: The groups did not differ on any of the baseline endpoints. Weight, body mass index, and waist circumference significantly decreased after treatment in Group B, but not in the other Groups. Liraglutide significantly increased LH (3.2±0.2 IU/L vs. 2.0±0.3 IU/L; p<0.01), FSH (2.6±0.2 IU/L vs. 1.6±0.3 IU/L; p<0.01), total testosterone (4.1±0.5 ng/mL vs. 1.4±0.6 ng/mL; p<0.05), and sex hormone-binding globulin (36.0±4.0 nmol/L vs. 14.0±3.0 nmol/L) levels from baseline, while no improvement was observed in the other Groups. Liraglutide increased sperm concentration (16±4 mil/ml vs. 6±2 mil/ml; p<0.05), progressive motility (34±4 % vs. 14±2 %; p<0.01), and morphology (10±2 % vs. 4±2 %; p<0.05), while treatment with gonadotropins only increased sperm progressive motility (19±2 % vs. 12±3 %; p<0.05) compared to baseline. The IIEF-5 score improved after liraglutide treatment (4±2 vs. 21±4; p<0.05), while no significant changes were observed in the other Groups. Similarly, PDE5i use decreased significantly in Group B (31%), compared with Groups A (48%) and C (45%). Conclusions: Liraglutide is an effective weight loss drug, which also improves serum gonadotropin and total testosterone levels, sperm conventional parameters, and sexual function in obese patients with functional hypogonadism seeking parenthood. This is the first study documenting the efficacy of liraglutide on the testicular function of these patients. Presentation Date: Saturday, June 17, 2023
format Online
Article
Text
id pubmed-10554582
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105545822023-10-06 OR25-02 Hunting The Magic Bullet In Treating Male Secondary Hypogonadism Associated With Metabolic Syndrome: Results Of a Prospective Study Comparing Liraglutide Vs. Gonadotropins La Vignera, Sandro Condorelli, Rosita A Calogero, Aldo E Cannarella, Rossella Greco, Emanuela Aversa, Antonio J Endocr Soc Reproductive Endocrinology Disclosure: S. La Vignera: None. R.A. Condorelli: None. A.E. Calogero: None. R. Cannarella: None. E. Greco: None. A. Aversa: None. Background: Previously, we hypothesized a role for glucagon-like peptide-1 (GLP1) analogs in the treatment of male infertility (DOI: 10.1111/andr.13015), although no studies have so far investigated this issue. Purpose: To prospectively investigate the effects of treatment with liraglutide, a GLP1 analog, on reproductive and sexual function in men with functional hypogonadism of childbearing age. Patients and Methods: 110 obese men of childbearing age (18-35 years) with functional hypogonadism were enrolled and divided into three groups based on their desire to have children. Group A consisted of men actively seeking paternity, Group B of men who did not seek paternity, and Group C of men who had already fathered a child. Group A was treated with gonadotropins [urofollitropin 150 IU three times a week and human chorionic gonadotropin (hCG) 2000 IU twice a week], Group B with liraglutide (3 mg daily), and Group C with transdermal testosterone (60 mg daily). The following endpoints were measured at enrolment and after 4 months: anthropometric and metabolic parameters, gonadotropins, total testosterone, conventional sperm parameters (Group A and B only), the score of the International Index of Erectile Function 5 Items (IIEF5), and frequency of phosphodiesterase type 5 inhibitors (PDE5i) use. Results: The groups did not differ on any of the baseline endpoints. Weight, body mass index, and waist circumference significantly decreased after treatment in Group B, but not in the other Groups. Liraglutide significantly increased LH (3.2±0.2 IU/L vs. 2.0±0.3 IU/L; p<0.01), FSH (2.6±0.2 IU/L vs. 1.6±0.3 IU/L; p<0.01), total testosterone (4.1±0.5 ng/mL vs. 1.4±0.6 ng/mL; p<0.05), and sex hormone-binding globulin (36.0±4.0 nmol/L vs. 14.0±3.0 nmol/L) levels from baseline, while no improvement was observed in the other Groups. Liraglutide increased sperm concentration (16±4 mil/ml vs. 6±2 mil/ml; p<0.05), progressive motility (34±4 % vs. 14±2 %; p<0.01), and morphology (10±2 % vs. 4±2 %; p<0.05), while treatment with gonadotropins only increased sperm progressive motility (19±2 % vs. 12±3 %; p<0.05) compared to baseline. The IIEF-5 score improved after liraglutide treatment (4±2 vs. 21±4; p<0.05), while no significant changes were observed in the other Groups. Similarly, PDE5i use decreased significantly in Group B (31%), compared with Groups A (48%) and C (45%). Conclusions: Liraglutide is an effective weight loss drug, which also improves serum gonadotropin and total testosterone levels, sperm conventional parameters, and sexual function in obese patients with functional hypogonadism seeking parenthood. This is the first study documenting the efficacy of liraglutide on the testicular function of these patients. Presentation Date: Saturday, June 17, 2023 Oxford University Press 2023-10-05 /pmc/articles/PMC10554582/ http://dx.doi.org/10.1210/jendso/bvad114.1701 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Reproductive Endocrinology
La Vignera, Sandro
Condorelli, Rosita A
Calogero, Aldo E
Cannarella, Rossella
Greco, Emanuela
Aversa, Antonio
OR25-02 Hunting The Magic Bullet In Treating Male Secondary Hypogonadism Associated With Metabolic Syndrome: Results Of a Prospective Study Comparing Liraglutide Vs. Gonadotropins
title OR25-02 Hunting The Magic Bullet In Treating Male Secondary Hypogonadism Associated With Metabolic Syndrome: Results Of a Prospective Study Comparing Liraglutide Vs. Gonadotropins
title_full OR25-02 Hunting The Magic Bullet In Treating Male Secondary Hypogonadism Associated With Metabolic Syndrome: Results Of a Prospective Study Comparing Liraglutide Vs. Gonadotropins
title_fullStr OR25-02 Hunting The Magic Bullet In Treating Male Secondary Hypogonadism Associated With Metabolic Syndrome: Results Of a Prospective Study Comparing Liraglutide Vs. Gonadotropins
title_full_unstemmed OR25-02 Hunting The Magic Bullet In Treating Male Secondary Hypogonadism Associated With Metabolic Syndrome: Results Of a Prospective Study Comparing Liraglutide Vs. Gonadotropins
title_short OR25-02 Hunting The Magic Bullet In Treating Male Secondary Hypogonadism Associated With Metabolic Syndrome: Results Of a Prospective Study Comparing Liraglutide Vs. Gonadotropins
title_sort or25-02 hunting the magic bullet in treating male secondary hypogonadism associated with metabolic syndrome: results of a prospective study comparing liraglutide vs. gonadotropins
topic Reproductive Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554582/
http://dx.doi.org/10.1210/jendso/bvad114.1701
work_keys_str_mv AT lavignerasandro or2502huntingthemagicbulletintreatingmalesecondaryhypogonadismassociatedwithmetabolicsyndromeresultsofaprospectivestudycomparingliraglutidevsgonadotropins
AT condorellirositaa or2502huntingthemagicbulletintreatingmalesecondaryhypogonadismassociatedwithmetabolicsyndromeresultsofaprospectivestudycomparingliraglutidevsgonadotropins
AT calogeroaldoe or2502huntingthemagicbulletintreatingmalesecondaryhypogonadismassociatedwithmetabolicsyndromeresultsofaprospectivestudycomparingliraglutidevsgonadotropins
AT cannarellarossella or2502huntingthemagicbulletintreatingmalesecondaryhypogonadismassociatedwithmetabolicsyndromeresultsofaprospectivestudycomparingliraglutidevsgonadotropins
AT grecoemanuela or2502huntingthemagicbulletintreatingmalesecondaryhypogonadismassociatedwithmetabolicsyndromeresultsofaprospectivestudycomparingliraglutidevsgonadotropins
AT aversaantonio or2502huntingthemagicbulletintreatingmalesecondaryhypogonadismassociatedwithmetabolicsyndromeresultsofaprospectivestudycomparingliraglutidevsgonadotropins